Stock Yards Bank & Trust Co. Has $2.57 Million Stock Position in The Clorox Company $CLX

Stock Yards Bank & Trust Co. grew its position in The Clorox Company (NYSE:CLX) by 1.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 21,423 shares of the company’s stock after acquiring an additional 300 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Clorox were worth $2,572,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CLX. Hsbc Holdings PLC grew its holdings in shares of Clorox by 118.8% in the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock valued at $159,699,000 after buying an additional 589,544 shares during the period. Robeco Institutional Asset Management B.V. grew its holdings in shares of Clorox by 101.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock valued at $130,123,000 after buying an additional 546,761 shares during the period. KBC Group NV grew its holdings in shares of Clorox by 688.7% in the 1st quarter. KBC Group NV now owns 587,679 shares of the company’s stock valued at $86,535,000 after buying an additional 513,171 shares during the period. AQR Capital Management LLC grew its holdings in shares of Clorox by 412.1% in the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock valued at $88,167,000 after buying an additional 481,846 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Clorox by 147.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 707,005 shares of the company’s stock valued at $104,107,000 after buying an additional 421,453 shares during the period. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Trading Up 0.9%

Shares of NYSE:CLX opened at $123.30 on Friday. The company’s 50-day moving average price is $122.81 and its two-hundred day moving average price is $129.64. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The Clorox Company has a one year low of $116.53 and a one year high of $171.37. The stock has a market capitalization of $15.08 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.98 and a beta of 0.52.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period in the previous year, the firm posted $1.82 EPS. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.0%. Clorox’s payout ratio is 76.07%.

Analysts Set New Price Targets

CLX has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Clorox from $133.00 to $135.00 and gave the company a “neutral” rating in a report on Monday, September 8th. Wells Fargo & Company cut their price objective on shares of Clorox from $130.00 to $125.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 25th. Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Clorox in a research report on Saturday, September 27th. Finally, Morgan Stanley cut their price objective on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. One analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $134.08.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.57% of the stock is owned by company insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.